Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era by Chalmers, Don et al.
REVIEW Open Access
Has the biobank bubble burst?
Withstanding the challenges for sustainable
biobanking in the digital era
Don Chalmers1*, Dianne Nicol1, Jane Kaye2, Jessica Bell2, Alastair V. Campbell3, Calvin W. L. Ho3, Kazuto Kato4,
Jusaku Minari4, Chih-hsing Ho8, Colin Mitchell2, Fruzsina Molnár-Gábor5, Margaret Otlowski1, Daniel Thiel6,
Stephanie M. Fullerton7 and Tess Whitton1
Abstract
Biobanks have been heralded as essential tools for translating biomedical research into practice, driving precision
medicine to improve pathways for global healthcare treatment and services. Many nations have established specific
governance systems to facilitate research and to address the complex ethical, legal and social challenges that they
present, but this has not lead to uniformity across the world. Despite significant progress in responding to the
ethical, legal and social implications of biobanking, operational, sustainability and funding challenges continue to
emerge. No coherent strategy has yet been identified for addressing them. This has brought into question the
overall viability and usefulness of biobanks in light of the significant resources required to keep them running. This
review sets out the challenges that the biobanking community has had to overcome since their inception in the
early 2000s. The first section provides a brief outline of the diversity in biobank and regulatory architecture in seven
countries: Australia, Germany, Japan, Singapore, Taiwan, the UK, and the USA. The article then discusses four waves
of responses to biobanking challenges. This article had its genesis in a discussion on biobanks during the Centre for
Health, Law and Emerging Technologies (HeLEX) conference in Oxford UK, co-sponsored by the Centre for Law and
Genetics (University of Tasmania). This article aims to provide a review of the issues associated with biobank practices
and governance, with a view to informing the future course of both large-scale and smaller scale biobanks.
Keywords: Biobanks, Sustainable biobanking, Comparative review, Medical research ethics, Genetics and genomics,
Personalised medicine, Precision medicine
Background
Over the past 20 years, there has been considerable in-
vestment in biobanking and research infrastructure in
scientifically- advanced countries because of the per-
ceived research benefits they provide. Biobanks are vari-
able in size and purpose, and may comprise single user,
disease-specific tissue and data collections or multi-user,
population banks, or anything in between [1]. Meir et al.
broadly define biobanks as: ‘collection[s] of biological
samples and associated data, systematically organized for
use by stakeholders, such as researchers and health care
providers’ [2]. This definition is expansive enough to
include conventional tissue banks and other collections,
such as bloodspots from newborn screening programs.
Although some mention is made of these collections
later in this article, it is not the intention of the article to
address the particular issues associated with these types
of collections. Rather, this article focuses primarily on
biobanks that are established and maintained specifically
for use by multiple researchers.
In essence, these research-focused biobanks comprise
collections of human tissue linked with genetic, genea-
logical, health and other personal information, which
can be used for a number of research purposes and from
which a multitude of different datasets can be extracted
[3, 4]. They are seen to accelerate the research effort be-
cause researchers do not have to expend valuable time
and funds on the collection, storage and curation of
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human tissue samples and data. The research power of
biobank datasets is considerably enhanced if they can be
combined with equivalent datasets from other biobanks,
but the provisos are that there must be uniformity in the
ways that they are collected, extracted and coded and
that ethical, legal and social implications (ELSI) are ap-
propriately taken into account. The greatest value comes
from these rich resources if they can be combined to-
gether in the form of ‘Big Data’ [5] for use in addressing
research questions of global significance.
The early 21st century saw a significant upsurge in
public and private investment in the establishment of
new research-focused biobanks. According to a BCC
market research report published in 2011, the global bio-
banking market was $141 billion in 2010, and was pro-
jected to increase by 30 % between 2010 and 2015, to an
estimated $183 billion [6]. Investment has been focused
on the establishment of population biobanks and cohort
studies as well as the organisation of existing smaller
collections under broader research infrastructure. This
coincides with considerable investment in sequencing
technology and the funding of research consortia and
disease networks with specific research objectives. How-
ever, this funding commitment has not been sustained in
all countries, as Australia and Singapore have seen with-
drawal of funding from biobanks.
Public funds have also been invested in small–scale
biobanks, which may be disease or project specific, as
well organ banks and repositories of samples derived
from clinical pathology [1]. More recently, public fund-
ing has been invested in the establishment of inter-
national collaborative consortia, to enhance the research
power of biobank data sets that may be considerably
strengthened if they are combined with equivalent data
sets from other biobanks and data repositories.
This article starts with a review of biobank initiatives
in some of the most research-active countries globally,
together with a brief overview of the key aspects of their
regulatory frameworks. This sets the scene for a broader
review of the key challenges for biobanking over the past
twenty years. This review is demarcated by three separ-
ate ‘waves’. The first wave saw particular focus on the
local and global governance frameworks that needed to
be put in place to ensure that the particular ELSI of bio-
banking were appropriately addressed. In the second
wave, the focus was directed towards standardisation
and harmonisation to facilitate combination and sharing
of biobank datasets. The third wave of challenges fo-
cuses on the financial sustainability of biobanking. Fund-
ing for biobank maintenance has always been a
challenge [1], but it has come into sharp focus recently
as funders question their commitment to providing
support in perpetuity. This article then looks prospect-
ively to a future ‘fourth wave’, where we propose that
technological developments and new strategies for com-
munity engagement could coalesce and, where complex
infrastructures and financial burdens are minimised
without compromising the research value of biobanking
or public trust in the biobanking enterprise.
The global environment for biobanking:
investment, infrastructure and governance
The brief country-by-country review presented in this
part is intended to illustrate the variability of approaches
to biobanking and biobank governance. In parallel with
investment and the international priority of building in-
frastructure for research, new governance structures for
biobanking have emerged. Some countries have intro-
duced biobank-specific legislation while others have
included provisions in existing law or delegated the re-
sponsibility to national bodies to develop guidance on
biobanking. In addition, many of the bigger and more
recent biobanks have developed internal ethics and gov-
ernance oversight frameworks, including guidelines and
policies [7].
Australia
Since the 2000s, Australia has seen the implementation
of a number of mostly disease specific biobanking facil-
ities. The premier national funding agency, the National
Health and Medical Research Council (NHMRC) largely
supported these biobanks, with a focus on cancer. Sam-
ples and clinical data in breast, prostate, ovarian, leukae-
mia, lymphoma and other blood cancers were collected
and stored, involving some very large disease cohorts, as
well as rare and more general cancers. In alignment with
the international movements on good governance, the
NHMRC included a chapter on databanks in the 2007
edition of the National Statement on Ethical Conduct in
Human Research [8] and also issued an Information
Paper on Biobanks in 2010 [9], which provided guidance
on many issues relating specifically to biobanking proce-
dures. In 2011, the Commonwealth Department of
Industry, Innovation, Science and Research (DIISR)
issued a Strategic Roadmap for Australian Research
Infrastructure for sector review [10]. This Roadmap ac-
knowledged the key role of biobanking in health re-
search and also in underpinning population health
research platforms. In 2013 the national budget to fund
biobanking was cut, significantly affecting the landscape
for biobanking in Australia.
Germany
Germany saw a rise in the number of biobanks for spe-
cific disease-related research as well as diagnostic and
research needs of healthcare institutions in the early
2000s, with federal government support for biobanking
continuing. Since 2011, five centralised biobanks (cBMBs)
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within the ‘National Initiative for Biomaterial Banks’
have been funded by the German Federal Ministry for
Education and Research (BMBF), recently extending
the promotion to a sixth biobank alliance. In 2013, the
BMBF set up the German Biobank Node (GBN). The
BMBF has also promoted six German Centres of Health
Research (DZG) equipped with biobanks within its Health
Research framework program. These are inter-centre
initiatives for combatting widespread diseases. Since
2014, the ‘National Cohort’, a cross-financed large-
scale study involving 200,000 participants for over ten
years at 18 research centres, has been brought under
the aegis of the GBN, which thus functions as the
central contact point and networking agent for the
biobank community [11].
The German Ethics Council (known as the National
Ethics Council until 2007) published two extensive opin-
ions on biobanking in 2004 and 2010 [12, 13]. In the
second opinion, the Council made a detailed five-pillar
legislative proposal for the regulation of biobanks, aimed
at enhancing protection of donors’ interests, including at
the international level and recommended that statutory
provisions on human biobanks for research be passed
[13]. Following extensive discussions in the German
Bundestag in 2012, the proposed legislation, based on
the opinion of the Ethics Council, was rejected. The
main reasons for this rejection included lack of neces-
sity, absence of comparable legislation in other countries
and the perceived need to avoid bureaucratisation of
research [14]. This outcome was much to the relief of
German biobanks and research centres that feared the
existence of smaller biobanks would be compromised
if the legislation was passed, and that its adoption
(and forced secrecy) would hinder international co-
operation [15, 16]. More recently, in 2015, a group of
university lawyers drafted alternative draft legislation
on biobanks [17].
Japan
In Japan, several large-scale biobank projects have
started since the 2000s. One of the representative pro-
jects is Biobank Japan, started in 2003 and samples col-
lected from 200,000 patients [18]. The current focus of
Biobank Japan is to create a third phase of 38 common
diseases involving 100,000 patients [19]. Several diseases,
such as dementia and depression have been newly added
as target diseases. Another national scale project, the
National Center Biobank Network (NCBN) started in
2011 [20], to integrate their activities and to accelerate
the efficient use of the collected samples. This project is
run by the six National Centers for advanced and spe-
cialized medical care in Japan. Currently over 150,000
samples are attached to the network, organised in a sin-
gle database called “NCBN Electronic-Catalogue-based
Database” [21]. The latest project regarding large-
scale biobanking is the Tohoku Medical Megabank
Organization (ToMMo) [22] launched in 2012, as a
large-scale cohort study to promotes biobank activ-
ities and to collect samples from 150,000 participants.
By late 2015, ToMMo has completed a few thousand
whole genome sequences (WGS), and resulting data
have been used to construct a reference panel of
1,070 Japanese individuals [23].
In April in 2015, a new funding agency, the Japan
Agency for Medical Research and Development (AMED)
[24], was created for biomedical research and develop-
ment. The AMED has been revisiting its policy and pro-
ject managements regarding genome research and its
medical application. The interim report on the genomic
medicine by the Headquarters for Healthcare Policy in
the Japanese government [25] in July 2015, will serve as
a key guiding document for the AMED as well as other
related Ministries. This interim report states that while
several large biobanks have been established successfully,
they need to be proactively utilised for the implementa-
tion of clinical medicine. Strong emphasis is placed on
the term “genomic medicine” and its implementation.
This could be interpreted as indicative of pressure on
biobanks to demonstrate actual benefits to medicine and
society.
Singapore
In 2002, the Singapore Tissue Network (STN) was estab-
lished with public funding, and subsequently reconsti-
tuted as the Singapore Bio-bank (SBB), which was
intended to function as the national not-for-profit tissue
bank to facilitate translational and population-based
epidemiological research [26]. Apart from the SBB,
other sizeable tissue banks in Singapore include the
SingHealth Tissue Repository (STR) [27] and the National
University Health System Tissue Repository (NUHS TR)
[28]. Unlike the STR and the NUHS TR, which collect
mainly residual biological samples from patients, the SBB’s
collection was derived from researchers and, to a more
limited extent, from the STR and NUHS TR. However,
the SBB was discontinued in September 2011 due to
concerns over long-term operational viability and fi-
nancial sustainability, triggered by its low utilisation
rate [26, 29].
While a national-level biobank might not have been
evaluated to be a sustainable undertaking, a variety of
bio-specimen collections and practices have subsisted
and thrived in Singapore. This may have, in part,
prompted the enactment of the Human Biomedical
Research Act (HBRA) on 18 August 2015, which estab-
lishes a relatively comprehensive legal framework on re-
search involving human participants (other than clinical
trials) and their biological materials. This legislation
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essentially builds on the system of ethical guidelines in-
stituted by the government, on the advice and recom-
mendations of its Bioethics Advisory Committee (BAC)
report on ‘Human Tissue Research’ in November 2002
[30]. These guidelines apply to all locally registered med-
ical practitioners and publicly funded research [31]. The
ethical principles embodied in the guidelines include the
primacy of the welfare of tissue donors, the need for in-
formed consent and confidentiality, respect for the hu-
man body and sensitivity towards the religious and
cultural perspectives and traditions of tissue donors.
More recently, these principles have been applied by
the BAC in a set of more detailed guidance on bio-
banking and research involving human biological ma-
terials [32]. The new HBRA effectively formalises
these guidelines, rendering their requirements applicable
to all researchers and research institutions operating in
Singapore (regardless of the source of funding). The con-
tent of these ethical obligations is not substantively differ-
ent from the broad international framework for ethical
research conduct derived from the Nuremburg Code and
by the Council for International Organizations of Medical
Sciences. What is different is the incorporation of these
principles into legislation, giving greater weight in ensur-
ing compliance.
Taiwan
In April 2005, the Taiwanese government launched a
Biomedical Technology Island Plan in which a large-
scale population biobank was proposed as a governmen-
tal project to support biotech development and medical
research in Taiwan [33]. The Taiwan Biobank aims to
collect blood, plasma, urine and DNA samples from
200,000 healthy participants aged 30–70 to link with
their lifestyle, family history and health information as a
prospective cohort study for the development of perso-
nalised medicine [34]. In addition to the 200,000 healthy
individuals, the biobank has also planned to collaborate
with major hospitals in Taiwan to further recruit
100,000 participants from patients over the next decade
[35]. The collected data aims to be used to study the 12
most common complex diseases among Taiwanese, in-
cluding breast, lung, colon, and liver cancers, stroke,
Alzheimer and chronic kidney diseases. The Taiwan
Biobank is funded by the Ministry of Health and Welfare
(MOHW) and was established at the Institute of
Biomedical Sciences (IBMS) at Academia Sinica - the
highest national research institute in Taiwan.
In 2010, the Legislative Yuan (Parliament) passed the
Human Biobank Management Act (HBMA) as a legal
framework to regulate the establishment, management,
and applications of all types of biobanks in Taiwan. The
Act stipulates rules on informed consent and data secur-
ity, and requires that a biobank operator shall establish
an ethics committee to review and supervise matters re-
lated to the management of biobanks, including applica-
tions for access to data and information stored in the
biobanks [36]. In addition, it requires an external ap-
proval from an expert review board, which is organised
by the competent authority, to supplement the internal
review mechanism. The Act also stipulates rules on
benefit sharing for any profits derived from commercial
use received by an Operator and Biobank to the specific
population groups [36]. Finally, the Act includes penal-
ties for breaches of rules in the HBMA, specifically, if a
biobank operator breaches confidentiality by disclosing
participant identifiable personal data or information ob-
tained as a result of the research. Penalties will also be
imposed if a biobank operator fails to regularly publish
biobank research results or fails to establish an ethics
committee and submit prescribed biobank matters to
the ethics committee for review and supervision.
United Kingdom
Continuing its commitment to public investment, the
UK Government announced in the 2015 Spending
Review that it will invest over £5 billion in health re-
search and development by 2020 [37]. The Medical
Research Council (MRC) is a key funder in a variety of
partnerships including biobanking [38], and in addition
to the government, the Wellcome Trust (WT) is the
UK’s largest non-governmental source of funds for bio-
medical research, with donations totalling approximately
£13.9 billion [37]. In 2014, a consortium of funders
under the leadership of the MRC established the
National Tissue Directory and Co-ordination Centre,
with the aim of establishing a directory of biobanks
in the UK [39].
Following the success of the Human Genome Project
in the late 1990s, the UK government has invested heav-
ily in biobanking to translate clinical outcomes from
genomic data. New genetics research partnerships be-
tween the government-funded National Health Service
(NHS) and industry have been proposed since The NHS
Plan [40] and following considerable investment in sys-
tems to collect standardised and comparable data on
clinical history, consultations and investigations, and to
allow linkage across different data sets [39]. The exist-
ence of the NHS has meant that the UK is uniquely
well-positioned to generate valuable epidemiological
data [39].
The UK government (Department of Health), the
MRC, and the WT, together with the British Heart
Foundation, the Scottish Government, the Welsh
Assembly and the National Regional Development
Agency have invested £90,711,541 to date in UK
Biobank: the world’s largest large-scale, publicly funded,
population biobank. Core funding (MRC and WT) has
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been extended from July 2015 to the end of 2017 [41].
UK Biobank supports investigation into a range of com-
mon diseases occurring in the UK. Half a million partici-
pants have given broad consent to the use of data
collected at recruitment, and can re-consent for supple-
mentary data collections (e.g., brain imaging study).
Nearly 100,000 samples have been genotyped for re-
search use as part of the project [42].
The UK10K Rare Genetic Variants in Health and
Disease is a project established to use existing re-
search samples to characterise the genetic bases of
rare diseases through comparison of genotypes of af-
fected individuals with deeply phenotyped groups
from cohort studies [43]. The National Cancer Research
Institute (NCRI) Confederation of Cancer Biobanks is a
consortium of biobanks and bio sample collections based
in the UK [44].
Despite the UK’s leading position in biobanking, there
is as yet no specific legal framework for the governance
of genomic databases/biobanks. Instead, there is guid-
ance from the Health Research Authority that apply to
biobanks which mean that research ethics approval is
not needed for the use the samples stored in the biobank
as the biobanks take on responsibility for oversight of
the use of tissue as part of their Human Tissue authority
licence [45]. In the UK, there exists a multi-dimensional
nexus of law that applies to medical research on human
beings, based on a distinction between human material
(samples) and information relating to individuals and
their data [46].
United States of America
In the USA, biobanks have emerged as a key feature of
the research landscape over the past 15 years. In the
most comprehensive assessment to date in that country,
Henderson and colleagues surveyed 456 biobanks (out
of over 630 recruited participants) and observed signifi-
cant heterogeneity in organisational structure, size, pur-
pose and financial models. While most biobanks are
affiliated with academic and medical research institu-
tions, biobanks tied to public health delivery systems
(Kaiser, Mayo, Geisinger, Veteran’s Administration etc.)
and private entities, and numerous smaller scale and
disease-specific biobanks have also proliferated. The
National Institutes of Health (NIH) continues to be the
premiere source of funding and support for biobanks
across the country and the key locus of major biobank-
ing efforts such as those based at the National Cancer
Institute [47].
The fractured system of health care delivery and pay-
ment in the USA presents an impediment to creating a
population biobank akin to countries with more centra-
lised systems (e.g. UK, Canada, Estonia). However, the
NIH’s recently announced Precision Medicine Initiative
Cohort Program envisions a million individual strong
longitudinal cohort of research participants who will be
recruited, in part, by networking some of the aforemen-
tioned biobanks with newly funded collections [48].
Additionally, government public health departments
(particularly in the past 10 years) have developed bio-
banks comprised of residual samples from public health
surveillance programs such as Newborn Screening pro-
grams. These DBS biobanks generated controversy in
two states (Texas and Minnesota) resulting in the unfor-
tunate destruction of several million samples and the
concomitant failure to build public support for this re-
search endeavour [49]. Still the interest in turning this
resource in to a “research goldmine” [46] remains high
as several states continue to explore developing such
biobanks [50, 51]. Further the Newborn Screening
Translational Research Network was created at the NIH
in order to help the States that have created biobanks
for the use of residual samples to connect with re-
searchers interested in using them.
In 2015, amendments to the federal guidelines that
govern human subjects’ research protections (known as
the Common Rule) were proposed and are subject to
public comments. The controversial revisions, among
other measures, would require broad consent for all sec-
ondary research utilising biospecimens. This change
would apply even when the samples are de-identified,
thereby eliminating one of the traditional exemptions for
population health studies [49]. The impacts of this
change to the Common Rule for biobanks are not yet
known, though the prospect of gathering broad consent
for use of samples received mixed reviews from contrib-
utors to the government’s open call for comment on the
proposed changes.
The first wave – establishing biobank governance
and management frameworks
The initiatives of the countries, described above can be
seen as part of wider international trends and govern-
ance responses to biobanking and the development of
research infrastructure. In each of these countries there
has been considerable investment in building biobanking
co-ordinating networks as well as national and regional
biobanks. These biobank collections represented a cul-
mination of bioinformatic and biotechnological advance-
ments that have enabled storage of samples and data,
and linkage of data on a hitherto unprecedented scale.
This, in turn, entailed a shift from individual research pro-
jects to biobanks as platforms to support longitudinal
research projects. The typically large-scale and ongoing
nature of these complex biobanks also heralded con-
cerns in relation to consent, privacy, and other govern-
ance and security issues. Biobanks also enlivened debates
about ideas of public and private good [52, 54, 55].
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Whilst the establishment of population biobanks, as re-
sources for a vastly increased number of researchers, is
well recognised as one of their key public interest func-
tions, their establishment also led to the development of
bespoke governance models that have addressed the par-
ticular legal and ethical issues that they raise.
The emergence of biobanks for longitudinal research
created a major challenge to traditional ideas of consent
in health research [53, 56, 57]. Approaches to obtaining
consent from participants had to be reconceptualised;
primarily because, at the time samples are collected, fu-
ture research uses are unknown. The very nature of bio-
banks as research resources means that they will involve
prospective as yet unspecified research projects. From a
practical point of view, obtaining specific consent from
each participant for every separate research project for
which his or her samples and information are to be used
is challenging. This has led to a growing acceptance of
the notion of broad consent to future unspecified re-
search, as a practical solution with specific consent for
the taking of a sample and information and its storage
[51, 56]. However, it will be shown later in this paper
that new, more nuanced approaches to consent are
emerging.
Other debates included how to guard against potential
re-identifiability through sample coding [58]. The use of
linked data is a key element of the usefulness of bio-
banks, but at the same time this presents risks to partici-
pants’ confidentiality and privacy, particularly taking
account of the special and sensitive nature of human
genetic information [59]. Privacy law was and remains a
principal regulatory framework for biobanks, based on
the influential Organisation for Economic and Cultural
Development (OECD) Information Privacy Principles,
published in 1980. Broad adoption of these OECD prin-
ciples brought a measure of consistency to national ap-
proaches to privacy.
Apart from the privacy regime, national ethical codes
for research conduct generally underpinned a compre-
hensive national regulatory framework for the ethical
conduct for research covering all activities for the collec-
tion, storage and distribution of human tissue samples
and data with guidelines on consent to the use of stored
data for research. Public trust also emerged as an im-
perative for biobanks [60, 61]. It became clear that estab-
lishing and retaining public trust was central to the
success of biobanks, especially in the case of population
biobanks. This was demonstrated in the failure of one of
the earliest population biobank, the Icelandic Health
Sector Database (HSD) after the Iceland Supreme Court
ruling [62].
At this time, an effective governance framework be-
came widely accepted as an essential prerequisite to en-
gendering and maintaining public trust. Early in the
‘biobank revolution’, policy makers and commentators
began to recognise that the biobank phenomenon
stretched general research ethics guidelines, and that
specific governance frameworks were needed to guide
policy development across a range of issues including
consent, privacy and access. These, in time, have
emerged. Internationally, the OECD Guidelines on
Human Biobanks and Genetic Research Databases were
published in 2009 [63] and were contemporaneous with
an expansion of international collaborations. However,
the variability of biobank collections (e.g. size, scale,
health status of participants, scope of potential research
and nature of the collection) has presented challenges
for consistent regulatory responses.
These early biobanking initiatives and governance
frameworks were also influenced by local experience, de-
termined by local history, healthcare arrangements,
funding and other factors. It was recognised nationally
that improved governance practices were needed in the
form of external regulatory layers from legislation, ethics
codes and other codes of practice and guidelines, as well
as internal institutional governance arrangements. Con-
sistent with the OECD best practices [63], biobank gov-
ernance arrangements generally include an oversight
body and a system of regular reviews to ensure compli-
ance with developing governance, ethical and legal
standards [64].
The second wave - collaboration and
standardisation
The good governance wave in biobanking was paralleled
by an increased professionalisation of biobanking as an
‘emerging scientific and operational area’ in research
[65] and the development of quality management and
standards in sample collection, processing, storage and
data management. By the first decade of the 21st cen-
tury, it was recognised that biobanks needed to develop
more standardised and harmonised technical procedures
[66]. Biobanks provide platforms for collaboration [67].
Collaborative networks within the biobanking landscape
are widely seen as the most cost effective means of
accelerating translational research. Considerable invest-
ment was made in projects that encouraged standardisa-
tion and co-ordination of activities at national, regional
and international levels.
International and national collaborative research
networks
In Europe, two key collaborative mechanisms were the
Promoting Harmonisation of Epidemiological Biobanks in
Europe (PHOEBE) [68] and the Biomolecular Resources
Research Infrastructure (BBMRI) initiatives. PHOEBE was
a collaboration promoting harmonisation of epidemio-
logical biobanks, which ended in 2009. The BBMRI was
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established as an EU biobank infrastructure project build-
ing on existing resources and technologies. The main aim
of BBMRI was to develop an information technology con-
cept for the exchange of data between biobanks (at na-
tional and European levels) and strategies for biobank
material quality management, and also to present a posi-
tive and transparent image of biobanking. The BBMRI is
now recognised as a European Research Infrastructure
Consortium (ERIC), pulling together a broad range of bio-
banks operating to increase efficacy and excellence in re-
search of European interest [69]. A number of European
member states are full members of ERIC including the
UK that joined recently in 2015 [70].
At a national level, there are a number of examples of
co-ordinating activities. In Germany biobank operators
have been maintaining and updating their data in an
interactive manner in the German Biobank Registry
(GBR) which is a member of BBMRI-ERIC [71]. In the
USA, the Coriell Personalized Medicine Collaborative
(CPMC) [72] aims for better understanding the impact
of genome-informed medicine by combining a biobank
facility with modern microarray technology. Similarly,
the Australasian Biospecimen Network Association
(ABNA) established in 2001, provides online support for
those managing and engaged in biobanking to share in-
formation and organises an annual conference on
current topics. In Taiwan, a similar effort in networking
can be found in the Taiwan Clinical Trials Consortium
(TCTC) that was set up by the National Research
Programme for Biopharmaceuticals (NRPB) for promot-
ing clinical data sharing and integration for pharmaceut-
ical applications. In Singapore, the Singapore Tissue
Network (STN) was established in 2002 but was discon-
tinued in 2011, whereas in the UK, a co-ordination net-
work has just been established [39].
Standardisation
It became apparent that in order to derive optimal value
from these collaborative initiatives as a collective re-
source, standardisation of policies, practices and proce-
dures would also be required. This lead to the creation
of the Public Population Project in Genomics (P3G)
[73], an initiative funded by Genome Canada [74] to fa-
cilitate collaboration between many national biobanks
and to provide a public and accessible knowledge
database for the international population genomics
community.
At the international level, the International Society of
Biological Environmental Repositories (ISBER) has taken
a leading international role in standardising preservation
and storage of biobanked material. The ICGC is an ex-
emplar of efforts to facilitate and integrate data exchange
for close to 200 large-scale cancer research projects.
ICGC developed a regularly reviewed set of guidelines
for both open and controlled-access data sets. Addition-
ally, the World Medical Association (WMA) is in the
process of preparing a Declaration on Ethical Consider-
ations regarding Health Databases and Biobanks.
In should be noted, however, that standardisation pro-
cesses sometimes face strong resistance, particularly
from smaller biobanks because of concerns that they
might not be able to meet the benchmarks, resulting in
a threat to their existence. However, the trend in latest
funding guidelines shows that the establishment of com-
prehensive and generic standards for the relevant fields
of biobanking is required, including information tech-
nology networking, quality management, responsibilities
towards the public, advising biobanks, education and
training and last, but not least, considering ethical, legal
and social issues, such as the German system [75].
The standardisation of responses to significant ethical,
legal and social concerns is increasingly being seen at
the global level. UNESCO's International Bioethics
Committee (IBC) for example, considered, in its session
2013, the need to update its previous reflections on the
human genome and human rights and to put a special
focus on biobanks during its future work [76]. In its lat-
est report of September 2015, the IBC provides a brief
description of the ethical challenges associated with bio-
banking and provides practical recommendations for an
international registry of all existing biobanks, the condi-
tions of the moral acceptability of a broad consent from
biobank participants and the specific points for a model
of governance for biobanks. It calls on states and gov-
ernments to develop a trustworthy form of governance
for biobanks and a biobank secrecy but also to harmon-
ise the corresponding rules on data confidentiality and
ethics review at the international level [77].
The third wave – seeking sustainability amidst on
going challenges
At the early biobank establishment stage, and amidst
initial enthusiasm, issues regarding long-term viability,
and strategies for discontinuance of biobanks were
not at the forefront, unlike today, when policies em-
phasise the importance of addressing such issues from
the outset. Indeed, over the years, there has been in-
creasing focus on the responsibilities of biobanks with
regard to requirements for establishment, communica-
tion with participants and returning results back to
them. It has required a very delicate balance to get
the settings right for biobanks in order to promote
the full gamut of genomic research opportunities that
they are capable of supporting, and at the same time
ensuring adequate governance arrangements. Despite
this progress, many of the practical questions as well
as ELSI raised in the first wave of biobanking con-
tinue to be debated. There are also contested new
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debates regarding return of individually relevant results
[78–80] and incidental findings [81–84].
Sustainability concerns
At this time, it became evident that biobanks needed to
be more focussed on developing and maintaining sus-
tainable business practices. In an environment of rapid
technological change this has proven a demanding task.
Over a decade ago, Professor Hank Greely observed that
biobanks could be “staggeringly expensive” [85]. For
example, the National Cancer Institute has been said to
spend over $50 million a year on its basic biospecimen
resource infrastructure [86]. Vaught and colleagues have
insightfully noted, the “[t]ight economic realities in clin-
ical and research operations have spurred the need to
re-examine financial models that support the infrastruc-
ture of biobanking” [7].
In the Australian context, despite initial enthusiastic
adoption of biobanking, this country is undergoing a
“levelling off phase” where biobank sustainability and
continued funding are certainly emerging as key national
issues. The NHMRC established a National Biobanking
Strategy Committee that met during 2012–2013 and
recognised that, without a more stable core-funding
stream, the viability of many biobanks, especially
those established for cancer research, could not con-
tinue. In Germany, the German Biobank Symposium,
co-organised yearly by the GBN since 2012 and estab-
lished as the specific national experts’ event for biobank
research, put a focus in 2013, inter alia, on the question of
business and financial models for biobanking. It noted that
even well established, financially well-positioned biobanks
need long-term sustainability concepts to be able to main-
tain and provide samples [87]. Long-term sustainability
calls for setting up biobanks as research and technology
platforms in an interdisciplinary manner across different
research centres [88]. In Singapore, the SBB was dis-
continued in September 2011 as this large-scale re-
search infrastructure was evaluated to be unsustainable
operationally and financially, due to a number of concerns
including under-utilisation [29].
Sustainability is not a universal challenge and some
biobanks are clearly surviving and prospering. The UK
Biobank has had its funding extended [41] and, in
Taiwan, the Ministry of Health and Welfare (MOHW),
the main funding body of the Taiwan Biobank has se-
cured the funding for the next decade, demonstrating
the state’s plan to use biotechnology as its developmen-
tal niche. The new funding agency of Japan, Agency for
Medical Research and Development (AMED), also con-
tinue to support three major biobank projects with 5.1
billion yen for FY2016 though the funding is only for
maintaining the core biobank activities. Similarly, the
Biomolecular Resources Research Infrastructure (BBMRI)
was not only recognised as a European Research
Infrastructure Consortium but also awarded European
legal status in December, 2013 [69] Nevertheless,
many biobanks were subject to an “underlying belief
that at some point, [they] should be capable of be-
coming ‘self-sustaining’”[1] but this model is not often
achieved.
Cost-recovery has been touted as obvious solution to
this issue. Cost-recovery usually means a minimal fee is
charged, particularly for academic researchers, whist an
often significantly higher fee is charged of researchers
from commercial entities [e.g., [89]]. However, the few
reports on cost-recovery are not encouraging. The
Australian Breast Cancer Tissue Bank, for example, has
a cost recovery policy and process policy but recovers
negligible amounts of fees in relation to its operational
budget. Similar gloomy reports have been made by
Canadian biorepositories [90]. There is further concern
relating to cost-recovery; that many biobanks are not
fully being used for the purposes for which they were
established. In particular, the smaller biobanks tend to
have few requests for access [91]. This impacts on any
success that a cost-recovery model might have. Argu-
ably, a measure of biobanking success is the number of
outgoing samples [92]. Methods that have been sug-
gested as means to overcome this under-use problem
include, providing a “catalogue” of samples [91] and in-
creased importance of advertising and “market research
data” [1].
Public trust and commercialisation
A business model with a more commercial focus might
address some of the biobank funding sustainability is-
sues, however, such models may come with potential
grave consequences, if not introduced with caution as in
some countries commercialisation is prohibited. Past re-
search would suggest that the shift to commercialisation
of medical research is accompanied by unique, often
problematic, concerns [60, 93, 94]. Loss of public trust is
a particular concern whenever commercial consider-
ations enter the equation [95, 96]. The difficulty of
balancing commercialisation and biobanking is aptly
summarized in by Turner and colleagues: “Biobanks are
caught directly between the values and rights of the par-
ticipants and the potential commercial and scientific
value of the samples and data, and, at the same time,
have to construct a business model that will ensure the
long-term sustainability of the biobank” [97].
Redefining commercialisation activities and focussing
on the creation of knowledge rather than commodities
realigns commercialisation with notions of public
good. Qualitative research using deliberative democ-
racy methodology has shown that it is possible to
counter the ‘natural prejudice’ that many people have
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against commercialization through independent gov-
ernance of biobank resources and transparency with
regard to commercial involvement [98]. This is not-
withstanding that public trust in biobanks is inevit-
ably reduced where there is a commercial partner,
particularly an international commercial partner [94].
Indeed, loss of public trust has been connected with
the demise of certain biobanks in the past [67].
A need for new business models?
Integrating successful business strategies into biobanking
practices may change the practice of biobanking. Use of
advertising and marketing metrics have been suggested
as means to attract new funding partners. Commercial
marketing strategies may also have the added benefit of
re-invigorating traditional research sponsors. Conse-
quences of this integration are likely to shift the focus of
biobanking to fulfilling the metrics that result in funding
success. This may have unintended consequences if met-
rics are not reflective of the activities which provide
public benefit, or better health; the reason for which
they have been created. For example, if the metrics are
heavily skewed towards profit making activity it may
influence the types of practices undertaken including
preferring to sponsor industry-driven research above
entirely academic pursuits. Implementing models that
appear to commercialise or commodify biobanking
(and the samples they contain) may also negatively
affect public perceptions and donor support and
erode public trust. If metrics that measure biobank
success are to be introduced, they should be carefully
considered so that they may be accurately measured,
while at the same time reflect actual societal value in
order to be effective and useful long term. Further,
should there be more commercial connection in bio-
banking more research is required as to how to main-
tain public trust.
Watson and colleagues have suggested that there are a
number of metrics that could be used to assist in meas-
uring the sustainability of biobanks. These may include
“financial value”, “operational efficiency” and “social ac-
ceptability” [1]. They argue for better differentiation of
the categories of biobanks, so that the metrics are par-
ticular to the type of biobank (i.e. user, size, kind). They
also tentatively suggest that metrics for measuring bio-
bank sustainability should include value to society [1].
One suitable metric for measuring public benefit could
be success in research discovery. Another measure could
be actual use, or number of requests to access biobank
resources a biobank. Further metrics need to be devel-
oped to address the competing, but ultimately compat-
ible, interests of funders, researchers, participants and
other stakeholders, as well as the wider community, to
put a measure on biobank “value” [7].
Standardisation and accreditation may assist in en-
hancing the value of biobank resources and improving
their long-term sustainability. For example, many have
argued that standardisation or accreditation of human
tissue sample collections would improve the “quality”
of results, and would likely lead to increased applica-
tions for use of biobank resources operating under
these conditions [99]. Accreditation schemes of this
nature are being debated by international groups,
such as ISBER [95]. To date, there is no consistent
standardised biobank model which is generally accepted
nor which is proven to be the optimal paradigm. Whilst it
is unlikely that there will be a single business or oper-
ational biobank model, greater consistency is clearly a
desirable goal.
Underlying this “business model” analysis is a supple-
mentary but fundamental question on whether human
tissue banks are still necessary. The usefulness of phys-
ical human tissue samples for research needs to be con-
sidered against the backdrop of advancing technology in
whole genome sequencing (WGS) and its increasing ac-
cessibility. There is much promise in the information
provided by WGS. Some even argue that WGS data po-
tentially removes the need to keep physical tissue. How-
ever, the case for retention of physical human tissue
remains compelling and persuasive. Firstly, without
standardisation across samples, it is important that re-
searchers have access to material to ensure consistent
methods across materials in a study. Secondly, the reli-
ability of single WGS scans still depends upon the reli-
ability of the system and platform that produces the
results. Thirdly, modern genomic researchers are now
accepting the critical importance of linking genomic data
to clinical and environmental data. The WGS scans re-
quire supplementation and accurate links to relevant
lifestyle and other information. However, if convincing
evidence emerges showing that access to tissue is no
longer necessary this would dramatically impact on the
need for biobanks and would shift the focus away from
storage of biospecimen to data banks.
A fourth wave – biobank futures and new
biobank models
There are a number of recurring themes in biobank
debates that must be taken into account in consider-
ing the future of biobanking. These include, but are
not limited to: ongoing problems with the nature of
consent particularly whether broad consent is ethically
defensible; ensuring respectful and appropriate on-
going involvement and connection with participants;
retaining public trust in an increasingly commercia-
lised research environment; properly maintaining the
physical space required to store tissue; keeping up to
date with rapidly changing technology that may result
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in more accurate collection/storage/analysis; and, perhaps
most problematically, sustainability in a constrained fund-
ing environment [100].
The recurring debates regarding informed consent
have marshalled the concept of “dynamic consent”. Dy-
namic consent utilises modern communication tech-
niques to facilitate the recognised need for ongoing
interaction between a researcher and participant, allow-
ing them to make specific decisions regarding types of
research and participation (or withdrawal). According to
Kaye and colleagues,
Dynamic consent is a personalised, communication
interface to enable greater participant engagement in
clinical and research activities…This approach is
‘dynamic’ because it allows interactions over time; it
enables participants to consent to new projects or to
alter their consent choices in real time as their
circumstances change and to have confidence that
these changed choices will take effect [96].
One benefit of building dynamic consent into the bio-
bank model would be the capacity of greater interactions
with participant. Arguably, participants benefit because
their choices are respected over their lifetime and their
contributions to the biobank can continue to be utilised
for research purposes. Researchers may also benefit from
using this model for consent in a number of ways. First,
dynamic consent and related approaches to ongoing
contact may allow researchers to monitor the health of
the participant and their family members over time. Sec-
ondly, where limitations in original consent documents
may have otherwise prevented researchers from under-
taking new types of research, participants could be
recontacted for dynamic re-consent. It may also facilitate
recontacting of participants and their families to acquire
new tissue samples. This would be especially important
in the context of cancer tumours where each type of
cancer is increasingly understood to have its own dis-
tinctive heterogeneous genome identity. It is increasingly
important that tumours are available for sequencing.
Whilst the dynamic consent model clearly holds much
promise, its benefits require a cultural change for re-
searchers and investment in software that could be offset
by reduced costs of recruitment, re-contacting and re-
consenting.
Building on the dynamic consent model, we propose
the concept of a ‘walking biobank’. The basis of this idea
rests in substituting the collection and long-term storage
of tissue for the ongoing engagement of the participant
in genomic research. On this model the research partici-
pants themselves serve as the storage units of their
genomic material and the researcher, rather than
expending limited funds on the infrastructure to
maintain specimens in suspended animation, invites par-
ticipants in a contact database (through dynamic con-
sent models of contact) to ‘walk in’ to donate tissue or
information as required to address a specific research
question. The feasibility of the ‘walking biobank’ model,
of course, rests on continuing reductions in the costs of
DNA sequencing such that it will be cheaper to sample,
generate genomic information, store the resulting data
‘in silico’, and discard the leftover tissue, than to store
that tissue for (only potential) additional analysis. Sam-
ple collection and use would, therefore more closely re-
semble the way that blood samples obtained for clinical
purposes are currently analysed and discarded once re-
sults are verified. This ‘walking biobank’ model is not
without limitations. First, a key benefit of the traditional
model is that once participants have provided their sam-
ple they need have no further involvement with the bio-
bank, should they so choose. Nevertheless, if sample
collection were straightforward the model would have
the benefit of reminding participants of their continuing
involvement in research, which may be overlooked/
forgotten on the traditional model. Secondly, the
walking biobank model relies on participant willing-
ness to donate ‘on demand’, so placing a significant
burden on them, depending on the nature and fre-
quency of requests made by the biobank. However,
with many biobanks struggling to identify users inter-
ested in accessing currently stored samples, this may
or may not turn out to be a salient concern. Cer-
tainly, returning repeatedly to the same participants
for re-donation would increase the need for biobanks
to prove to participants that they should remain ac-
tive, and to keep their trust and engagement at a high
level. Thirdly, there are related sustainability, cost and
efficiency arguments with such on-going checks and
additional sample collection. Participant recontact, at-
tendance at the biobank and donation would involve
additional costs. Finally, the ‘walking biobank’ model
suggests that the death of a participant would prevent
further biospecimen collection and possibly see the de-
mise of the biobank that spans generations (although the
maintenance of derived data in databases would permit
continuing cross-generation comparison).
Some biobanks have already adopted a type of ‘hybrid
model’ involving both maintaining tissue collections and
long term relationships with participants and their fam-
ilies. For example, kConFab is a large breast and ovarian
cancer repository based in Australia, where. The reposi-
tory staff has formed close connections with donating
families who regularly provide additional tissue and
health or lifestyle information. Effectively, such reposi-
tories include aspects of the ‘walking biobank’ into their
operational model but have yet to move to more dy-
namic consent and still rely heavily on broad consent,
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facilitated through strong trust between participants and
the repository.
Another biobank initiative, referred to as the ‘virtual
biobank’, involves creating better indexes and data cata-
logues. Such improved data management systems have
led to the emergence of another new model. This has
been described as an ‘electronic database of biological
specimens and other related information, regardless of
where the actual specimens are stored’ [100]. The
‘virtual biobank’ model has the potential for broader use
of biobank resources by better connecting researchers to
the required materials, thus minimising duplication.
However, this ‘model’ does not resolve the significant
cost issues in relation to maintaining physical banks of
tissue, as it is based on the connection between, and
sharing biobank resources. The ‘virtual biobank’ model
also highlights the clear need for consistency and ac-
creditation of biobanks. There are some examples of
this virtual model in the USA, where the Office of
Biorepositories and Biospecimen Research (OBBR) cre-
ated the Biospecimens Research Network (BRN) and a
Biospecimen Resource Database (BRD). Once populated,
it will operate as a virtual biobank [97], but the funding
for the various components of the BRD is a matter of on-
going uncertainty. However, if numbers of applications in-
crease significantly, this may reinvigorate attempts to
introduce a cost-recovery model. In addition, in Sweden
the BARCdb alongside a database of samples, plans to
offer guidance in standardising state of the art processes
to increase value and utility in samples [98]. This, or simi-
lar standardisation, may provide sufficient basis for a vir-
tual model to exist and promote increased usage.
Conclusion
This article does not propose that the biobank bubble
has burst, but it suggests that there are challenges that
require mechanisms to be put in place to transform
current practices. It is predicted that the vastly expensive
population-wide biobank model is unlikely to survive in
its current form for much longer. Much academic litera-
ture details potential solutions, some outlined in this art-
icle, for the ongoing challenges experienced by biobanks.
Biobanks have attracted considerable investment over
the past twenty years, as they have been perceived as
having the potential to accelerate research and reduce
the time and costs of research by providing ready access
to large numbers of samples and data. More recently this
has been questioned. Biobanks have not reached a stage
of long-term sustainability even though it had been
thought initially that the burden of sustainability would
ease over time. This does not appear to be the case,
although reliable assessment is difficult to attain. Many
of the international and national bodies assisting bio-
banks to solve emergent challenges do not have access
to the resources required, so individual biobanks are
largely left to deal with significant challenges on their
own. A commitment by governments and funders to
funding biobanking as national, regional and inter-
national research infrastructure, from the public purse
would offer sustainability. However, this is simply not
possible for many countries.
In this fourth wave of innovation and activity, a shift
towards a more “customised” approach to biobanking
can be witnessed, with national and regional variations
depending upon circumstances and political support.
There is not yet a single dominant or accepted biobank
model but there is potential for aspects of traditional
models to be used in conjunction with other new initia-
tives to build innovative sustainability and business sys-
tems responsive to particular biobank needs. Moving to
more virtual models and the use of online technologies
to support dynamic consent and walking biobanks are
ways in which sustainability may be realised.
The evidence tends to support that the way forward
will be more individualised responses in terms of sus-
tainability and business models that incorporate quality
and operational standards to encourage sharing and fa-
cilitate linking, both in the electronic sense and as to the
use of physical materials. In this article, successive waves
of innovation in biobanking practice have been mapped
to provide some possibilities to address sustainability is-
sues in biobanking. The future may be unclear, but what
is certain is that sustainability is an issue that needs to
be resolved to enable biobanking to continue.
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